Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.15 USD | -4.24% | -0.54% | +48.36% |
Jun. 04 | Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating | MT |
Jun. 03 | Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial | CI |
- Stock Market
- Equities
- NVCR Stock
- News NovoCure Limited